GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brilacidin overview

Brilacidin (PMX-30063) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus, including MRSA and MSSA, encephalitic alphaviruses, including venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and sindbis virus (SINV), chemotherapy induced oral mucositis in patients with head and neck cancer who have received chemoradiation, ulcerative proctosigmoiditis, monkeypox, ulcerative proctitis, hidradenitis suppurativa, acne and atopic dermatitis, invasive pulmonary aspergillosis, ocular keratitis, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 associated cytokine storm and inflammatory bowel disease. It is administered through intravenous route, rectal route, topical, ophthalmic, auricular as well as orally. Brilacidin is a defensin mimetic compound which works as a bacterial cell membrane disruptor. The drug candidate is developed based on CDDT (computational drug design) technology. It was also under development for bacterial keratitis, lung infections, bacterial conjunctivitis, otitis media, vancomycin-resistant Enterococcus infections, diabetic foot wounds, ulcers caused by infections, bone and joint infections.

Innovation Pharmaceuticals overview

Innovation Pharmaceuticals, formerly Cellceutix, is a biopharmaceutical company that is engaged in the discovery and advancement of medical therapies with anti-infective, oncology, anti-inflammatory, and dermatology applications. Innovation Pharmaceuticals offers pipeline products such as Brilacidin, a defensin-mimetics compound with antimicrobial and immunomodulatory/anti-inflammatory properties, for the treatment of infectious diseases and Oral Mucositis. The company through its subsidiary, also offers image image-guided surgical laser platform. It conducts research, development, and commercialization of technologies and products in collaboration with various research institutions, pharmaceutical companies, and other third-party entities across the US and European countries. Innovation Pharmaceuticals is headquartered in Wakefield, Massachusetts, the US.

For a complete picture of Brilacidin’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.